Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset …
N Singh, C Wannstedt, L Keyes, T Gayowski… - …, 2005 - journals.lww.com
Background. The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …
[PDF][PDF] Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus‐seronegative liver transplant recipients of cytomegalovirus‐seropositive donor …
N Singh, C Wannstedt, L Keyes, D Mayher… - Liver …, 2008 - Wiley Online Library
The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus
(CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient …
(CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient …
[HTML][HTML] Management of cytomegalovirus infection and disease in liver transplant recipients
J Bruminhent, RR Razonable - World journal of hepatology, 2014 - ncbi.nlm.nih.gov
Cytomegalovirus (CMV) is one of the most common viral pathogens causing clinical disease
in liver transplant recipients, and contributing to substantial morbidity and occasional …
in liver transplant recipients, and contributing to substantial morbidity and occasional …
[PDF][PDF] Increased incidence of cytomegalovirus infection in high‐risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis
KT Shiley, LB Gasink, TD Barton… - Liver …, 2009 - Wiley Online Library
Optimal measures for the prevention of cytomegalovirus (CMV) in high‐risk orthotopic liver
transplant (OLT) patients are unknown. The charts of high‐risk OLT recipients with 12 …
transplant (OLT) patients are unknown. The charts of high‐risk OLT recipients with 12 …
Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients
C Díaz-Pedroche, C Lumbreras, R San Juan… - …, 2006 - journals.lww.com
Background. The role of valganciclovir in the prevention of cytomegalovirus (CMV) disease
in high-risk seropositive transplant patients is not known. Methods. We prospectively …
in high-risk seropositive transplant patients is not known. Methods. We prospectively …
Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus …
DJ Winston, RW Busuttil - Transplantation, 2004 - journals.lww.com
Cytomegalovirus (CMV)-seronegative liver transplant recipients with CMV-seropositive
donors have the greatest risk for CMV disease. We performed a randomized, controlled trial …
donors have the greatest risk for CMV disease. We performed a randomized, controlled trial …
Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in …
DJ Winston, RW Busuttil - Transplantation, 2003 - journals.lww.com
Background. Without effective antiviral prophylaxis, cytomegalovirus (CMV) disease is a
common cause of morbidity and mortality after liver transplantation. In this randomized …
common cause of morbidity and mortality after liver transplantation. In this randomized …
[PDF][PDF] Efficacy and safety of low‐dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
JM Park, KD Lake, JD Arenas… - Liver …, 2006 - Wiley Online Library
The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in
liver transplant recipients has not been established. We retrospectively compared the …
liver transplant recipients has not been established. We retrospectively compared the …
Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized …
N Singh, DJ Winston, RR Razonable, GM Lyon… - Jama, 2020 - jamanetwork.com
Importance Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral
prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive …
prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive …
[HTML][HTML] Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R-transplant recipients
N Perrottet, O Manuel, F Lamoth, JP Venetz… - BMC infectious …, 2010 - Springer
Background Valganciclovir, the oral prodrug of ganciclovir, has been demonstrated
equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients …
equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients …